Clinical trial
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult…
NCT04575597 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT04575597 |
|---|---|
| Title | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) |
| Official title | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19. |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Coronavirus Disease (COVID-19) |
| Intervention type | Drug |
| Interventions | Molnupiravir, Placebo |
| Enrollment | 1,735 |
| Start date | Oct 19, 2020 |
| Primary completion | May 5, 2022 |
| Completion | May 5, 2022 |
| First posted | Oct 5, 2020 |
| Last update posted | Jun 28, 2023 |
| Countries | Argentina, Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: